Sanofi India has reported results for fourth quarter and full year ended December 31, 2015.
The company has reported 29.95% rise in its net profit after exceptional items at Rs 120.20 crore as compared to Rs 92.50 crore for the same quarter in the previous year. The company’s total income has increased by 10.25% to Rs 581.13 crore for the quarter under review from Rs 527.10 crore for the corresponding quarter of the previous year.
For the full year, the company has reported 21.92% rise in its net profit after exceptional items at Rs 321.50 crore for FY15 as compared to Rs 263.70 crore in FY14. The company’s total income has increased by 9.93% to Rs 2244.50 crore for FY15 from Rs 2041.80 crore for the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: